Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sublingual buprenorphine-naloxone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

NCT06023459
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions
Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
Drug
Lead sponsor
Yih-Ing Hser
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 9, 2026, 12:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

NCT00000320
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine formulation: liquid vs. tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine for Treatment Resistant Depression

NCT01407575
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 4 Interventional

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

NCT00007527
View directory record Official record
Conditions
Opiate Dependence
Interventions
naloxone, buprenorphine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 9, 2026, 12:16 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Brenipatide, Placebo, Buprenorphine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 12:16 AM EDT
Terminated Phase 3 Interventional

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT03766893
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Buprenorphine/Naloxone Film Strips

NCT00640835
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone Film Strip
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Birmingham, Alabama • Haleyville, Alabama • Jacksonville Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 9, 2026, 12:16 AM EDT
Recruiting Phase 4 Interventional

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

NCT04375033
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
25
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 9, 2026, 12:16 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Individuals in Jail

NCT06306443
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
extended-release buprenorphine (XR-B)
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Medications Development for Drug Abuse Disorders

NCT01188421
View directory record Official record
Conditions
Opioid Related Disorders, Opioid Dependence, Opioid Addiction
Interventions
Buprenorphine/naloxone, Clonidine, Tramadol ER
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Terminated Phase 4 Interventional Results available

Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment

NCT04716413
View directory record Official record
Conditions
Acute Pain
Interventions
Dsuvia
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 9, 2026, 12:16 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 9, 2026, 12:16 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 9, 2026, 12:16 AM EDT